Developing local delivery of anti-androgen therapy – a novel treatment for prostate diseases.

Developing local delivery of anti-androgen therapy – a novel treatment for prostate diseases.

Developing local delivery of anti-androgen therapy – a novel treatment for prostate diseases.

We Are Alessa

Founded by Pamela Munster and her group at the UCSF Department of Medicine – division of Hematology and Oncology, Alessa is motivated by a shared goal: to create innovative advancements in oncology and the treatment of solid organ diseases.

Our Mission

Alessa Therapeutics is focused on developing effective therapy delivered selectively to the prostate.

Our Story

Alessa was founded by Dr. Pamela Munster, a leading oncologist at UCSF focused on developing novel strategies for patients with or at risk for cancer. Arising from a strong need to develop sustainable and tolerable new strategies for early interception and prevention of cancer, she founded Alessa Therapeutics to bring new tools to patients and change the treatment paradigm for early-stage cancers.

We Are Alessa

Founded by Pamela Munster and her group at the UCSF Department of Medicine – division of Hematology and Oncology, Alessa is motivated by a shared goal: to create innovative advancements in oncology and the treatment of solid organ diseases.

Our Mission

Alessa Therapeutics is focused on developing effective therapy delivered selectively to the prostate.

Our Story

Alessa was founded by Dr. Pamela Munster, a leading oncologist at UCSF focused on developing novel strategies for patients with or at risk for cancer. Arising from a strong need to develop sustainable and tolerable new strategies for early interception and prevention of cancer, she founded Alessa Therapeutics to bring new tools to patients and change the treatment paradigm for early-stage cancers.

Our Team

Cam Gallagher

President & CEO

Pamela Munster, MD

Founder, CSO, Director

Maithili Rairkar, PhD

Chief Technology Officer

Zach Collins, PhD

Chief Business Officer

Bonnie Wettersten

VP, Clinical Operations

Cam Gallagher

President & CEO

Pamela Munster, MD

Founder, CSO, Director

Maithili Rairkar, PhD

Chief Technology Officer

Zach Collins, PhD

Chief Business Officer

Bonnie Wettersten

VP, Clinical Operations

Cam Gallagher

President & CEO

Pamela Munster, MD

Founder, CSO, Director

Doug Crawford, PhD

Managing Partner, Mission BioCapital
General Manager, MBC Biolabs

Steve Tregay, PhD

Managing Partner, Mission BioCapital

Annie Mitsak

Partner, Cure Ventures

Richard Lim

Managing Partner, Cure Ventures

Pamela Munster, MD

Founder, CSO, Director

Cam Gallagher

President & CEO

Doug Crawford, PhD

Managing Partner, Mission BioCapital
General Manager, MBC Biolabs

Steve Tregay, PhD

Managing Partner, Mission BioCapital

Annie Mitsak

Partner, Cure Ventures

Richard Lim

Managing Partner, Cure Ventures

Our Pipeline

Our Clinical Trials

Alessa is currently conducting several clinical studies of minimally-invasive, drug delivery implantable systems in patients with prostate cancer. Our systems are designed to administer anti-androgen drugs to the tumor in the prostate in a sustained manner without systemic exposure.

Enolen
Biolen + RT
Biolen-PC

Our Clinical Trials

Alessa is currently conducting several clinical studies of minimally-invasive, drug delivery implantable systems in patients with prostate cancer. Our systems are designed to administer anti-androgen drugs to the tumor in the prostate in a sustained manner without systemic exposure.

Enolen
Biolen + RT
Biolen-PC

Our Science

Alessa is at the forefront in developing new and innovative localized, sustained drug delivery strategies for the treatment and early interception of cancer and other proliferative disorders.  We are developing drug-eluting implants and have completed initial human feasibility testing. Our leading efforts are focused on prostate cancer and benign prostate hyperplasia.

Prostate Cancer
Benign Prostate Hyperplasia

Our Science

Alessa is at the forefront in developing new and innovative localized, sustained drug delivery strategies for the treatment and early interception of cancer and other proliferative disorders.  We are developing drug-eluting implants and have completed initial human feasibility testing. Our leading efforts are focused on prostate cancer and benign prostate hyperplasia.

Prostate Cancer
Benign Prostate Hyperplasia

Latest Press Releases & News

See All Press Releases & News